OR WAIT 15 SECS
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
San Francisco - Despite the importance of knowing which of the numerous treatment modalities should be used as first-line treatment for basal cell carcinoma (BCC), there is a severe lack of well-designed, randomized, controlled trials to evaluate the different treatment options, according to Jan Bong, M.B., C.H.B., M.R.C.P., of Queen's Medical Centre, University of Nottingham.